Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

8.640 -0.870 (-9.15%)

Streaming Delayed Price Updated: 12:43 PM EST, Feb 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	188,178
Open	9.520
Bid (Size)	8.600 (100)
Ask (Size)	8.680 (400)
Prev. Close	9.510
Today's Range	8.400 - 9.650
52wk Range	4.600 - 12.62
Shares Outstanding	29,798,399
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Elicio Therapeutics Reports Inducement Grants

January 16, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

December 16, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+7.3%	+7.3%
1 Month	+11.6%	+11.6%
3 Month	-2.0%	-2.0%
6 Month	-0.1%	-0.1%
1 Year	+6.8%	+6.8%

More News

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

December 11, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

November 19, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

November 07, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

November 03, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

October 27, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

September 29, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

September 18, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

September 17, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

August 12, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio (ELTX) Q2 Loss Beats Estimates ↗

August 07, 2025

Via The Motley Fool

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 07, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

August 05, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 30, 2025

Via Benzinga

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

June 17, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Secures $10 Million in Financing

June 04, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 13, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

April 16, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 01, 2025

Via Benzinga

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

March 31, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

March 24, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 21, 2025

Via Benzinga

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 30, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Elicio Therapeutics, Inc. - Common Stock publicly traded?

Yes, Elicio Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Elicio Therapeutics, Inc. - Common Stock trade on?

Elicio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Elicio Therapeutics, Inc. - Common Stock?

The ticker symbol for Elicio Therapeutics, Inc. - Common Stock is ELTX on the Nasdaq Stock Market

What is the current price of Elicio Therapeutics, Inc. - Common Stock?

The current price of Elicio Therapeutics, Inc. - Common Stock is 8.640

When was Elicio Therapeutics, Inc. - Common Stock last traded?

The last trade of Elicio Therapeutics, Inc. - Common Stock was at 02/10/26 12:43 PM ET

What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock?

The market capitalization of Elicio Therapeutics, Inc. - Common Stock is 257.46M

How many shares of Elicio Therapeutics, Inc. - Common Stock are outstanding?

Elicio Therapeutics, Inc. - Common Stock has 257M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.